DK0774251T3 - 3R-3'R stereoisomer af zeaxanthin til behandling af degeneration af macula hos mennesker - Google Patents

3R-3'R stereoisomer af zeaxanthin til behandling af degeneration af macula hos mennesker

Info

Publication number: DK0774251T3
Authority: DK; Denmark
Prior art keywords: zeaxanthin; macular degeneration; humans; cells; stereoisomer
Prior art date: 1995-10-31

Application number

DK96307928T

Other languages

Danish (da)

English (en)

Inventor

Kevin M Garnett

Dennis L Gierhart

Luis H Guerra-Santos

Original Assignee

Zeavision L L C

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-31

Filing date

1996-10-31

Publication date

2004-11-22

1995-10-31 Priority claimed from US08/550,665 external-priority patent/US5747544A/en

1995-10-31 Priority claimed from US08/551,153 external-priority patent/US5827652A/en

1995-10-31 Priority claimed from US08/551,166 external-priority patent/US5854015A/en

1996-10-31 Application filed by Zeavision L L C filed Critical Zeavision L L C

2004-11-22 Application granted granted Critical

2004-11-22 Publication of DK0774251T3 publication Critical patent/DK0774251T3/da

Links

JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 title abstract 5
JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 title abstract 5
QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 title abstract 5
JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 title abstract 5
KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 title abstract 5
229940043269 zeaxanthin Drugs 0.000 title abstract 5
235000010930 zeaxanthin Nutrition 0.000 title abstract 5
239000001775 zeaxanthin Substances 0.000 title abstract 5
208000002780 macular degeneration Diseases 0.000 title abstract 3
229940088594 vitamin Drugs 0.000 abstract 2
229930003231 vitamin Natural products 0.000 abstract 2
239000011782 vitamin Substances 0.000 abstract 2
150000003722 vitamin derivatives Chemical class 0.000 abstract 2
241001136276 Sphingobacterium multivorum Species 0.000 abstract 1
206010064930 age-related macular degeneration Diseases 0.000 abstract 1
230000001580 bacterial effect Effects 0.000 abstract 1
235000015872 dietary supplement Nutrition 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
229940126585 therapeutic drug Drugs 0.000 abstract 1
235000013343 vitamin Nutrition 0.000 abstract 1
235000019195 vitamin supplement Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Dispersion Chemistry (AREA)
Ophthalmology & Optometry (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Botany (AREA)
Organic Chemistry (AREA)
Food Science & Technology (AREA)
Nutrition Science (AREA)
Molecular Biology (AREA)
Polymers & Plastics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

DK96307928T 1995-10-31 1996-10-31 3R-3'R stereoisomer af zeaxanthin til behandling af degeneration af macula hos mennesker DK0774251T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/550,665 US5747544A (en)	1995-10-31	1995-10-31	Method of using pure 3R-3'R stereoisomer of zeaxanthin to treat or prevent retinal degeneration in humans
US08/551,153 US5827652A (en)	1995-10-31	1995-10-31	Zeaxanthin formulations for human ingestion
US08/551,166 US5854015A (en)	1995-10-31	1995-10-31	Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion

Publications (1)

Publication Number	Publication Date
DK0774251T3 true DK0774251T3 (da)	2004-11-22

Family

ID=27415594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96307928T DK0774251T3 (da)	1995-10-31	1996-10-31	3R-3'R stereoisomer af zeaxanthin til behandling af degeneration af macula hos mennesker

Country Status (7)

Country	Link
EP (1)	EP0774251B1 (de)
AT (1)	ATE270882T1 (de)
CA (1)	CA2188983C (de)
DE (1)	DE69632898T2 (de)
DK (1)	DK0774251T3 (de)
ES (1)	ES2225863T3 (de)
TW (1)	TW586930B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL1010351C2 (nl) *	1998-10-19	2001-01-08	Werklust & Beheer B V	Esters van caroteno´den voor gebruik in de preventie en behandeling van oogaandoeningen.
US20030228392A1 (en)	2002-06-06	2003-12-11	Wyeth	Infant formula compositions containing lutein and zeaxanthin
US9192586B2 (en)	2003-03-10	2015-11-24	Zeavision Llc	Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20090118227A1 (en)	2007-11-07	2009-05-07	Bristol-Myers Squibb Company	Carotenoid-containing compositions and methods
DK2473065T3 (en)	2009-09-02	2016-06-27	Omniactive Health Tech Ltd	Xanthophylls-COMPOSITION CONTAINING macular PIGMENTS AND A MANUFACTURING METHOD THEREOF

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3891504A (en)	1970-07-31	1975-06-24	Hoffmann La Roche	Process for the manufacture of zeaxanthin
BE790289A (fr)	1971-10-27	1973-02-15	Nestle Sa	Procede de fabrication de zeaxanthine
CH572981A5 (de)	1973-07-26	1976-02-27	Nestle Sa
US4153615A (en)	1978-03-27	1979-05-08	Hoffmann-La Roche Inc.	Method of producing coloring agents
DE3119383A1 (de)	1981-05-15	1982-12-02	Basf Ag, 6700 Ludwigshafen	Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinodpraeparaten
US4737462A (en)	1982-10-19	1988-04-12	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
KR920006865B1 (ko)	1984-05-18	1992-08-21	워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드	입자나 액적을 피복하는 방법과 장치
US4851339A (en)	1986-04-01	1989-07-25	Hills Christopher B	Extraction of anti-mutagenic pigments from algae and vegetables
US5227507A (en)	1987-03-27	1993-07-13	Hoffmann-La Roche Inc.	Ethynylcyclohexene compounds and processes for manufacture thereof
DK171297B1 (da)	1987-03-27	1996-08-26	Hoffmann La Roche	Fremgangsmåde til fremstilling af cyclohexenderivater som mellemprodukter til fremstilling af zeaxanthin samt cyclohexenderivater
US5180747A (en)	1989-02-28	1993-01-19	Nisshin Flour Milling Co., Ltd.	Stabilized fat-soluble vitamin compositions
US5429939A (en)	1989-04-21	1995-07-04	Kirin Beer Kabushiki Kaisha	DNA sequences useful for the synthesis of carotenoids
DE69018117T2 (de) *	1989-04-21	1995-10-26	Kirin Brewery	Zur Synthese von Karotinoiden verwendbare DNA-Sequenzen.
US5290605A (en) *	1989-06-29	1994-03-01	Niva Shapira	Sun-exposure nutritional supporting composition
ATE153700T1 (de)	1989-08-30	1997-06-15	Applied Food Biotech Inc	Verfahren zur herstellung einer zeaxanthin enthaltenden zusammensetzung mittels eines mikroorganismus der spezies flavobacterium multivorum
DE4141351A1 (de)	1991-12-14	1993-06-17	Basf Ag	Stabile pulverfoermige vitamin- und/oder carotinoid-praeparate und verfahren zu deren herstellung
DE4200728A1 (de)	1992-01-14	1993-07-15	Basf Ag	Stabile, fluessige praeparate fettloeslicher substanzen
US5310764A (en)	1992-05-08	1994-05-10	Steven Baranowitz	Treatment of age related macular degeneration with beta-carotene
US5382714A (en)	1994-03-17	1995-01-17	The Catholic University Of America	Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof
DK0831797T3 (da) *	1995-06-07	2007-04-02	Howard Foundation	Farmaceutisk aktive carotenoider

1996
- 1996-10-28 CA CA002188983A patent/CA2188983C/en not_active Expired - Lifetime
- 1996-10-31 ES ES96307928T patent/ES2225863T3/es not_active Expired - Lifetime
- 1996-10-31 DE DE69632898T patent/DE69632898T2/de not_active Expired - Lifetime
- 1996-10-31 DK DK96307928T patent/DK0774251T3/da active
- 1996-10-31 EP EP96307928A patent/EP0774251B1/de not_active Expired - Lifetime
- 1996-10-31 AT AT96307928T patent/ATE270882T1/de not_active IP Right Cessation
- 1996-11-28 TW TW085114674A patent/TW586930B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
ATE270882T1 (de)	2004-07-15
EP0774251A3 (de)	1997-06-18
TW586930B (en)	2004-05-11
EP0774251B1 (de)	2004-07-14
EP0774251A2 (de)	1997-05-21
CA2188983A1 (en)	1997-05-01
ES2225863T3 (es)	2005-03-16
CA2188983C (en)	2001-02-27
DE69632898T2 (de)	2005-08-04
DE69632898D1 (de)	2004-08-19

Publication	Publication Date	Title
AU6586896A (en)	1997-04-10	Fatty acid treatment
EP0755633B1 (de)	1999-10-27	Zwei-Phasen-Präparat
WO2004069190A3 (en)	2005-06-23	Combination therapy for treating protein deficiency disorders
NO20063328L (no)	2006-09-19	Anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav
KR940018089A (ko)	1994-08-16	내부조직의 방사선 손상에 대한 예방 및 처치방법
EP0249735A3 (de)	1990-01-10	Als aktives Mittel 2-Phenyl-1,2-benzisoselenazol-3(2H)-on enthaltende pharmazeutische Zubereitungen zur Behandlung von durch oxidativen Stress verursachten Krankheiten
AU4879596A (en)	1996-09-11	Amino acid compositions and use thereof in clinical nutrition
DE69632898D1 (de)	2004-08-19	3R-3'R Diastereoisomer von Zeaxanthin zur Behandlung von der Degeneration der Macula
MD1633B2 (en)	2001-03-31	Application of lysozyme dimer and method of non-specific cellular and humoral stimulation of mechanisms for immune system protection and for prophylaxis and treatment of immunodepressant state or diseases relating to it
ATE110274T1 (de)	1994-09-15	Mittel zur verbesserung spezifischer eigenschaften des blutes.
Gordon	1981	Elderly depressives: treatment and follow-up
FI980947A7 (fi)	1998-04-29	Zeaksantiinin puhdas 3R-3'R-stereoisomeeri silmän keltatäplämuutoksen hoitamiseksi
ATE283060T1 (de)	2004-12-15	Verwendung einer pollenextrakt-haltigen verbindung zur behandlung hormon-assoziierter erkrankungen
EE9700231A (et)	1998-04-15	Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks
AU8643698A (en)	1999-02-22	Controlled release pharmaceutical compositions containing tiagabine
EP0402208A1 (de)	1990-12-12	Mischung von Vitamin A in physiologischer Dosis und verschiedenen Wirkstoffen mit therapeutischer Wirksamkeit
ATE293445T1 (de)	2005-05-15	Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
CN105997962A (zh)	2016-10-12	辅酶q10在治疗周期性麻痹疾病中的应用
Lebedev	1996	Selenium deficiency in patients with cardiovascular diseases and its correction with the drug" selena"
RU2053786C1 (ru)	1996-02-10	Способ профилактики иммунодефицитных состояний
IL322616A (en)	2025-10-01	A method for treating Raynaud's disease or erectile dysfunction
MD2164G2 (ro)	2003-11-30	Metodă de tratament al contuziilor oculare
UA10235A (uk)	1996-12-25	Спосіб корекції дезадаптаційних розладів організму
MD2068F1 (en)	2003-01-31	Method of treatment of the Herpes simplex infection
Fayed	2016	Stress and Autoimmune Diseases